Clinical Trial

Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.

Study acronym: ONSET
Recruiting
View on ClinicalTrials.gov →
Summary
This is an observational study to evaluate the effectiveness and safety of secukinumab in participants with AS who have never used TNFi, JAKi, or IL-17i drugs before.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-25; most recent amendment 2026-02-19.
Status change: Not Yet Recruiting → Recruiting 2025-04-29
Trial Details
NCT Number NCT06905288
Lead Sponsor Novartis Pharmaceuticals
Conditions Ankylosing Spondylitis
Enrollment 70 participants
Start Date 2025-04-02
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-23